跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
歐 聰億
主治醫師
,
臺北市立萬芳醫院
https://orcid.org/0000-0001-9093-1615
電子郵件
93023
w.tmu.edu
tw
h-index
819
引文
16
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2003
2025
每年研究成果
概覽
指紋
網路
研究成果
(70)
類似的個人檔案
(6)
指紋
查看啟用 Tsong Yih Ou 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Infection
78%
Bacteremia
77%
Colistimethate
56%
Acinetobacter Baumannii
53%
Mortality Rate
51%
Pathogen
46%
Sepsis
43%
Urinary Tract Infection
39%
Tigecycline
37%
Combination Therapy
35%
Chronic Liver Disease
32%
Hepatitis B Virus
32%
Hepatitis C
32%
Hemodialysis
30%
Intensive Care Unit
29%
Antibiotics
24%
Healthcare Associated Infection
24%
Escherichia coli
23%
Bloodstream Infection
21%
Antibiotic Resistance
21%
Hospital Mortality
17%
Apoplexy
17%
Klebsiella pneumoniae
17%
COVID-19
16%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Omicron Coronavirus Variant
16%
Emphysematous Cholecystitis
16%
Clostridium
16%
Elizabethkingia Meningoseptica
16%
Malaria Falciparum
16%
Cohort Analysis
16%
Disinfectant Agent
16%
Tocilizumab
16%
Pneumocystis Jirovecii
16%
Caspofungin
16%
Therapy Resistance
16%
Hyperbilirubinemia
16%
Abdominal Infection
16%
Achromobacter Xylosoxidans
16%
Meropenem
16%
Fosfomycin
16%
Lemierre's Syndrome
16%
Delftia acidovorans
16%
Ventricular Septal Defect
16%
Weil's Disease
16%
Plasma Exchange
16%
Penicillinase
16%
Chryseobacterium indologenes
16%
Necrotizing Fasciitis
16%
Brain Abscess
16%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Acinetobacter Baumannii
54%
Bacteremia
52%
Colistimethate
52%
Infectious Agent
46%
Tigecycline
44%
Urinary Tract Infection
43%
Mortality Rate
40%
Cohort Study
32%
Combination Therapy
26%
SARS Coronavirus
25%
Bloodstream Infection
21%
Fatality
21%
Antibiotic Resistance
21%
Respiratory Tract
19%
Clinical Trial
18%
Sepsis
18%
Hospital Infection
17%
Cerebrovascular Accident
17%
Klebsiella pneumoniae
17%
Chryseobacterium indologenes
16%
Elizabethkingia Meningoseptica
16%
Healthcare Associated Infection
16%
Alpha Enolase
16%
Vibrio Cholerae
16%
Ecological Study
16%
Delftia acidovorans
16%
Therapy Resistance
16%
Single Chain Fragment Variable Antibody
16%
Candida Albicans
16%
Malaria Falciparum
16%
Tocilizumab
16%
Lemierre's Syndrome
16%
Achromobacter Xylosoxidans
16%
Jaundice
16%
Hemagglutinin
16%
Disease
16%
Hepatitis C
16%
Hepatitis B Virus
16%
Chronic Liver Disease
16%
Randomized Controlled Trial
16%
Ropeginterferon Alpha2b
16%
Meropenem
16%
Normal Human
16%
Immunogenicity
16%
Influenza Vaccine
16%
Penicillinase
16%
Abdominal Infection
16%
Influenza A Virus (H7N9)
16%
Brain Abscess
16%
Nursing and Health Professions
Intensive Care Unit
39%
Infection
39%
Cohort Analysis
32%
Urinary Tract Infection
32%
Emergency Ward
32%
Sepsis
25%
Healthcare Associated Infection
22%
Hospital Infection
19%
Patient with Diabetes
19%
Surgical Intensive Care Unit
17%
Cerebrovascular Accident
17%
Bloodstream Infection
17%
Vancomycin-Resistant Enterococcus
16%
Tocilizumab
16%
Blood Culture
16%
Ventilator-Associated Pneumonia
16%
Care Bundle
16%
Ritonavir
16%
Teaching Hospital
16%
Bacterial Load
16%
Disinfectant Agent
16%
Bladder Catheterization
16%
Severe Acute Respiratory Syndrome
16%
Surgical Ward
16%
Urinary Catheter
14%
Infection Control
8%
Bacterium Culture
8%
Infection Rate
7%
Diabetes Mellitus
7%
Clinical Feature
6%
Confidence Interval
6%
Fomite
6%
Sodium Chloride
6%
Hazard Ratio
5%
